Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azacitidine - AbbVie

Next Previous
Drug Profile

Azacitidine - AbbVie

Latest Information Update: 25 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Allergan
  • Developer AbbVie
  • Class Antineoplastics; Aza compounds; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Myelodysplastic syndromes
  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 09 Feb 2022 Phase-II clinical trials in Acute myeloid leukaemia (Treatment-naive, In adults, In the elderly) in USA (IV) (NCT04905810)
  • 10 Sep 2020 Phase-III clinical trials in Myelodysplastic syndromes (Combination therapy, First-line therapy) in Australia, Austria, Belgium, Canada, China, Czech Republic, Germany, France, Hungary, Italy, Japan, South Korea, Netherlands, Poland, Puerto Rico, Russia, Spain, Turkey, Taiwan, United Kingdom (SC) (NCT04401748; EudraCT2020-000744-55)
  • 10 Sep 2020 Phase-III clinical trials in Myelodysplastic syndromes (Combination therapy, First-line therapy) in Taiwan, Turkey, United Kingdom, Spain, Russia, Puerto Rico, Poland, Netherlands, South Korea, France, Italy, Japan, Hungary, Germany, Czech Republic, China, Canada, Australia, Belgium (IV) (NCT04401748; EudraCT2020-000744-55)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top